相关实验视频

Updated: Jul 16, 2025

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

人类乳杆菌和胰岛素的协同作用通过调节db/db小鼠肠道微生物群的组成和代谢资料来降低高血糖

Peifan Li¹, Tong Tong¹, Yusong Wu¹

¹College of Biochemical Engineering, Beijing Union University, Beijing, 100023, P.R. China.

Journal of microbiology and biotechnology

|September 21, 2023

概括

益生菌Limosilactobacillus fermentum和Lactiplantibacillus plantarum与胰岛素改善了糖尿病小鼠的肠道微生物群和代谢资料. 这种干预降低了血糖,调节了关键的微生物通路,为2型糖尿病治疗提供了潜力.

科学领域:

微生物学和免疫学
代谢障碍代谢障碍代谢障碍
胃肠病学胃肠病学

背景情况:

2型糖尿病是一个全球性健康问题,病因复杂.
肠道微生物群失生症越来越多地被认为是代谢疾病的一个因素.
益生菌和益生菌显示出调节肠道健康和代谢功能的潜力.

研究的目的:

研究Limosilactobacillus fermentum和Lactiplantibacillus plantarum与胰岛素结合在2型糖尿病小鼠模型 (db/db小鼠) 中对肠道微生物群组成和代谢概况的影响.
探索这种益生菌-益生菌干预在缓解2型糖尿病症状方面的潜力.

主要方法:

db/db小鼠接受了Limosilactobacillus fermentum和Lactiplantibacillus plantarum与胰岛素 (LI组) 或对照组的12周的治疗.
用16S rRNA测序分析了肠道微生物组成.
代谢概况通过非向的代谢量学来评估.
评估了禁食血糖水平和结肠组织特征.

主要成果:

与模型对照组相比,LI组的禁食血糖水平显著降低,结肠组织增强.
LI干预改变了肠道微生物群,减少了有害细菌 (Corynebacterium,Proteus) 和恢复了有益的属 (Lachnospiraceae_NK4A136_组,Lachnoclostridium,Ruminococcus_gnavus_组,Desulfovibrio,Lachnospiraceae_UCG-006). 这种干预改变了肠道微生物群,减少了有害细菌 (Corynebacterium,Proteus),恢复了有益的属 (Lachnospiraceae_NK4A136_组,Lachnoclostridium,Ruminococcus_gnavus_组,Desulfovibrio,Lachnospiraceae_UCG-006).
代谢分析显示,LI逆转了特定代谢物的变化,包括罗塔乌斯特林,5-氧乙酸,13(S) -HpODE,L-氨酸和L-氨酸.
相关性分析表明,Lachnoclostridium和Ruminococcus_gnavus_group与参与酸,托和血清突触调节的代谢途径有关.

结论:

乳酸菌与胰岛素 (LI) 结合,有效调节肠道微生物群,并改善db/db小鼠的代谢概况.
这种干预可以通过调节特定的微生物丰度和代谢途径来缓解2型糖尿病的症状.
这些发现表明,通过向肠道微生物群调节,对2型糖尿病有潜在的治疗策略.

关键词:

人类乳杆菌家族 (Lactobacillaceae)我们的肠道微生物群.在这种情况下,胰岛素和胰岛素是不同的,而胰岛素和胰岛素是不同的.代谢生物组的代谢生物组 2型糖尿病是什么?

更多相关视频

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...